Importantly, the latest WHO classification of central nervous system tumors now distinguishes two metabolic phenotypes of adult GBM based on the molecular assessment of a specific TCA cycle mutation (isocitrate dehydrogenase, IDH), namely into grade 2-4 gliomas (IDH-mut) and grade 4 GBM (IDH-wt) (Park et al., 2023). This evidence concerns the gene IDH3A and central nervous system cancer.